Spyre Therapeutics, Inc. SYRE Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$179.44M+14.1% | -$155.2M+25.4% | -$148.97M+30.7% | -$206.81M-11.2% | -$208.93M+42.6% | ||
| $41.56M+4.2% | $37.61M-16.1% | $37.02M-30.0% | $40.55M-9.1% | $39.88M+5.5% | ||
| -$185.63M-9.3% | -$169.25M-7.5% | -$161.87M-7.0% | -$154.18M+1.4% | -$169.86M-53.3% | ||
| -$86.83M— | -$143.48M— | -$66.61M— | —— | —— | ||
| $321.16M+34.4% | $309.03M-24.8% | $221.81M-36.4% | $239.24M-28.8% | $238.87M-56.2% | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Spyre Therapeutics, Inc. generate?
- Spyre Therapeutics, Inc. (SYRE) generated -$185.6M in operating cash flow over the trailing twelve months.
- Where does Spyre Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Spyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.